Abstract
Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have